Celgene Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease

Date : 07/19/2019 @ 7:47PM
Source : Dow Jones News
Stock : Celgene Corporation (CELG)
Quote : 95.58  -0.1 (-0.10%) @ 5:33PM

Celgene Says FDA Approves Otezla for Oral Ulcers in Behcet's Disease

Celgene (NASDAQ:CELG)
Historical Stock Chart

2 Months : From Jun 2019 to Aug 2019

Click Here for more Celgene Charts.

By Michael Dabaie

 

Celgene Corp. (CELG) said the U.S. Food and Drug Administration approved Otezla 30 mg twice daily for adults with oral ulcers associated with Behcet's Disease.

Behcet's Disease is a rare, chronic, multisystem inflammatory disease that is difficult to treat, Celgene said. Otezla reduced the number and pain of oral ulcers in a 12-week placebo-controlled Phase 3 study.

Otezla is now approved for three indications in the U.S., including the treatment of patients with moderate to severe plaque psoriasis, the company said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

July 19, 2019 14:32 ET (18:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest CELG Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.